Market revenue in 2022 | USD 223.9 million |
Market revenue in 2030 | USD 380.7 million |
Growth rate | 6.9% (CAGR from 2022 to 2030) |
Largest segment | Hormonal therapy |
Fastest growing segment | Hormonal Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Other Drug Class, Hormonal Therapy |
Key market players worldwide | Johnson & Johnson, Astellas Pharma Inc, Eli Lilly and Co, Sanofi SA, Ipsen SA, Bayer AG, AstraZeneca PLC, Bausch Health Companies Inc, Merck & Co Inc, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer therapeutics market will help companies and investors design strategic landscapes.
Hormonal therapy was the largest segment with a revenue share of 88.43% in 2022. Horizon Databook has segmented the Spain prostate cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy, other drug class, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain prostate cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Spain prostate cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account